Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials - Wikidata - awgldk - TriplyDB

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

http://www.wikidata.org/entity/Q35408148

about

Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy Drugs for type 2 diabetes: role in the regulation of bone metabolism Bone: incretin hormones perceiver or receiver?The alliance of mesenchymal stem cells, bone, and diabetes Diabetes, bone and glucose-lowering agents: clinical outcomes.The use of incretins and fractures - a meta-analysis on population-based real life data.Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus.Dipeptidyl peptidase-4 inhibitors and prevention of bone fractures: Effects beyond glyemic control.Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial.Adipocyte Accumulation in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and Bone Regeneration Sitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced OsteoporosisIn Vivo and Inhibits RANKL-Induced Osteoclast Formation and Bone Resorption In Vitro.The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.Incretin action on bone: An added benefit?Incretin-based medications for type 2 diabetes: an overview of reviews.Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.Impact of oral antidiabetic agents on bone metabolism.Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins.Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs.Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients.Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.Safety of Anti-Diabetic Therapies on Bone.High Levels of Serum DPP-4 Activity Are Associated with Low Bone Mineral Density in Obese Postmenopausal Women.Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism.Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials.The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups.Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.Diabetes and sex: from pathophysiology to personalized medicine.Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.Evolving therapeutic options for type 2 diabetes mellitus: an overview.Antidiabetic therapy effects on bone metabolism and fracture risk.The prevention of fragility fractures in diabetic patients.Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.Linagliptin: an update of its use in patients with type 2 diabetes mellitus.Diabetes medications and bone.

P2860

Q26750278-4F4038D0-4D79-4617-8CE7-1AB46A2AF2B9 Q26775763-F516A48F-EED7-433D-8226-0970E106DE6D Q27008949-2A7AA4BB-E329-4CCE-9CCF-07367E623A89 Q27012497-CDE37580-871F-43DE-B113-AF87A426065D Q30234622-30B98D8D-8DA6-4ADE-9C37-9E955F313B14 Q31138952-39C84D5E-17E9-44C2-8D74-E5268A3E3C85 Q33412360-CB81C87D-556C-4361-A82F-79DBFDCE513D Q33603342-9FC0DC64-2B3E-42E9-A3D7-BD06ED3BEE61 Q33603384-5C5E69A8-0F57-430D-B81C-DA7A8BE6B60E Q33691585-DC687742-CB88-4951-ADA1-E99EFF2C85D9 Q33765723-2471FB72-7228-454B-B377-F05AA14AE08A Q33857358-AD5E436C-453F-40A7-A2CB-3E9F6C3A16F8 Q33867998-6DA17878-EEA1-4F97-9E9F-E03355B0D49E Q35571799-AB5B03E4-97C4-4458-B9FB-004D683AA1B0 Q35577601-B18BB44B-A126-44A4-9C9F-F40643D982B0 Q35817205-7045B0BE-71BA-4C9E-A0EF-DA6C2C1D752E Q35877767-C90C2C96-F17A-4797-8BE4-8FA63194EA16 Q35964678-B7C3A214-28B2-4E64-B0BA-E665B93A7343 Q36137808-DB304BFC-240D-4BF1-9A9C-53E84403F035 Q36254518-37EE8239-D1CC-4AEF-A493-4C337866D0B8 Q36358775-D8FC25FD-E2E2-40C4-8665-E0EBDC17435F Q36410243-105A4470-0E9F-4D58-BAD7-F4703FFD22D8 Q36431670-E9553BB3-AA56-43BD-829A-BDC739934EC6 Q36716222-64B8151F-7C47-4588-B0C3-CA28A041126A Q36717067-E5AD8E9B-5292-4247-8D1A-D51DBBA2B792 Q36911447-31788690-3BDA-4639-B8FA-10A1978123F6 Q36935346-EDE13E98-2FF8-4729-92E5-7CA3B4B9AA73 Q37072773-C35F20A5-6F02-49DF-8B89-7D722576BA88 Q37502682-F4B3307C-1F6A-45F2-9C82-BB2203672B8F Q37511845-812F6BED-5CCE-4D05-94A3-D6529BC0C9C8 Q37992956-A6A64625-3004-43A2-B5DB-096F6DBEF785 Q38015162-19AA48A3-E3D8-44A0-8AED-7BD53DC5E138 Q38052846-62EE7BEA-CB65-4EB1-9AA1-D0D42D8E790B Q38062881-D69F340E-267A-4222-A986-EEFCF167279E Q38074336-A37AEA64-4A57-4F7A-9524-166B0FFC5308 Q38078009-EF70EFC5-ECDE-48C5-9EBF-A13456508721 Q38233593-5F55CCBF-B7CD-4A75-A217-B76ACD334CD9 Q38235219-DA9F2AD5-1759-494C-B91B-0B16BF35A48C Q38258278-0F8F65C0-6ADE-4C91-AD1F-FF860CDB041B Q38272637-98F56F04-8F46-4A77-970B-CC0A931325F8

P2860

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

http://www.wikidata.org/entity/Q35408148

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@ast

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@en

type

label

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@ast

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@en

prefLabel

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@ast

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@en

P1433

Q35408148-BD96C3D5-2736-47D2-AB3B-F24A45164F40

P1476

Q35408148-1BE5561E-9F41-4EE6-B2F8-7E485EA045CA

P2093

Q35408148-6B24C270-AAC4-4343-8E5D-AD53D5874D6F

Q35408148-AB5BC407-BA51-4383-AE3D-EBBC3B4B371D

Q35408148-BF0BD6E9-93D2-4929-AE01-94324875C63F

P2860

Q35408148-0037BD1F-8A04-426D-A6EB-DDEA558F2FB2

Q35408148-042DCC68-B13D-4415-9191-99729D012E83

Q35408148-04C14FA0-55DB-40F2-BDDF-1AD16E2CDDC1

Q35408148-108E0F6A-3AF9-4303-882B-36881A5FAA31

Q35408148-5A0A1821-AD76-49A6-A300-B356C7EE178B

Q35408148-5BC5FD84-79AA-43A0-BDC4-D24DDA6BD769

Q35408148-6310BFE0-E098-4A92-9800-7BCB5B5FAF6F

Q35408148-70200D00-F21D-4995-B546-C6F685F3BB6F

Q35408148-782FB3CA-8A33-46FB-990F-715C6EF0DF97

Q35408148-795D543D-38C6-4DC0-88B6-AFEA72B899AD

P304

Q35408148-2F65A000-ADEB-44BC-B7C5-21CF6DC693ED

P31

Q35408148-7D365570-4BB5-4BF9-A7C6-42996F2DC23E

Q35408148-d787f118-d0db-4183-a709-7d19f1eb8b9a

P356

Q35408148-F0A4619D-9F70-4950-917E-F7053593EE33

P407

Q35408148-9ED687A2-9E29-43B7-A086-14B89305A329

P433

Q35408148-71DB20D1-834A-412A-9A4C-14644DFC1F5B

P478

Q35408148-C81B9795-E29F-43CD-AF7D-99FF215E1EAF

P50

Q35408148-BE180EC1-C818-4534-8459-8F27AE42234B

P577

Q35408148-D7B7FB4B-1551-493C-8C6F-098E6E720B3F

P5875

Q35408148-E1C44858-1CBE-4349-A8F6-06334F0C0E87

P698

Q35408148-4562AC40-96AF-4044-B5F9-DC614A4E247E

P932

Q35408148-475E403F-DB86-43F4-AA7E-7F5238454034

P356

P1433

P1476

Dipeptidyl peptidase-4 inhibit ...... of randomized clinical trials

@en

P2093

Alessandro Antenore

http://www.w3.org/2001/XMLSchema#string

Edoardo Mannucci

http://www.w3.org/2001/XMLSchema#string

Matteo Monami

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Operating characteristics of a rank correlation test for publication bias

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

Biology of incretins: GLP-1 and GIP

GIP and GLP-1, the two incretin hormones: Similarities and differences

The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

P304

2474-2476

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC11-1099

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Ilaria Dicembrini

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51743865

http://www.w3.org/2001/XMLSchema#string

P698

22025784

http://www.w3.org/2001/XMLSchema#string

P932

3198283

http://www.w3.org/2001/XMLSchema#string